Loading clinical trials...
Loading clinical trials...
This study will look at the effect on the QTc interval and pharmacokinetics after multiple dosing in subjects with HER2-expressing metastatic and/or unresectable breast cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Collaborators
NCT04654208 · Malignant Neoplasm of Breast
NCT04030507 · Breast Cancer, HER2-positive Breast Cancer, and more
NCT07067138 · Breast Cancer, Breast Carcinoma, and more
NCT06878248 · Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), and more
NCT07042581 · Breast Cancer, Stage 0 Breast Cancer, and more
Kanagawa Cancer Center
Yokohama, Kanagawa
National Cancer Center Hospital
Chuo Ku, Tokyo
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Koto-Ku, Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions